Danaher Co. (NYSE:DHR) Director John T. Schwieters sold 10,578 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $100.30, for a total value of $1,060,973.40. Following the completion of the sale, the director now owns 29,531 shares of the company’s stock, valued at $2,961,959.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Danaher Co. (DHR) opened at $99.57 on Wednesday. The stock has a market capitalization of $70,335.93, a price-to-earnings ratio of 25.02, a price-to-earnings-growth ratio of 2.12 and a beta of 1.04. Danaher Co. has a twelve month low of $78.97 and a twelve month high of $104.82. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05.
Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the business earned $1.05 EPS. The company’s revenue was up 10.9% on a year-over-year basis. equities research analysts forecast that Danaher Co. will post 4.37 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. Zions Bancorporation raised its stake in Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after purchasing an additional 667 shares during the period. Patten Group Inc. raised its stake in Danaher by 262.3% during the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock valued at $114,000 after purchasing an additional 3,497 shares during the period. First Personal Financial Services raised its stake in Danaher by 128.9% during the 4th quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock valued at $114,000 after purchasing an additional 691 shares during the period. Calton & Associates Inc. acquired a new stake in Danaher during the 4th quarter valued at $114,000. Finally, CNB Bank acquired a new stake in Danaher during the 4th quarter valued at $116,000. 77.05% of the stock is currently owned by institutional investors.
A number of equities research analysts have weighed in on DHR shares. Credit Suisse Group restated a “hold” rating and issued a $99.00 target price on shares of Danaher in a research report on Tuesday, December 19th. Zacks Investment Research downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Robert W. Baird restated a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Royal Bank of Canada restated a “hold” rating and issued a $96.00 target price on shares of Danaher in a research report on Thursday, January 4th. Finally, UBS Group started coverage on Danaher in a research report on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Danaher currently has a consensus rating of “Buy” and an average price target of $100.68.
TRADEMARK VIOLATION NOTICE: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3228043/insider-selling-danaher-co-dhr-director-sells-10578-shares-of-stock.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.